SCHEMBL6422020

SCHEMBL6422020

C=CCOc1cc(C(=O)O)ccc1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.52
TSHR P16473 3/20 0.49
GAA P10253 2/20 0.49
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
ATM Q13315 1/20 0.47
HTT P42858 2/20 0.46
PDE4B Q07343 1/20 0.46
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA4 P22748 1/20 0.45
CA6 P23280 1/20 0.45
CA7 P43166 1/20 0.45
TPMT P51580 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
MRGPRX4 Q96LA9 2/20 0.44
ALDH1A1 P00352 3/20 0.44
RAB9A P51151 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27279846 0.88 TSHR (0.52) KDM4ETSHRGAAHTTPDE4B
SCHEMBL15312851 0.85 KDM4E (0.60) KDM4ETSHRGAAHTTPDE4B
SCHEMBL9479071 0.85 KDM4E (0.53) KDM4ETSHRGAAKMT2APDE4B
SCHEMBL12126791 0.84 HSD17B2 (0.55) KDM4EGAAMEN1KMT2APDE4B
SCHEMBL14907128 0.83 KDM4E (0.74) KDM4ETSHRGAAHTTPDE4B
SCHEMBL3314219 0.83 KDM4E (0.66) KDM4ETSHRGAAHTTPDE4B
SCHEMBL31737057 0.83 KDM4E (0.74) KDM4ETSHRGAAHTTPDE4B
SCHEMBL7635214 0.83 TSHR (0.57) KDM4ETSHRGAAHTTPDE4B
SCHEMBL27051793 0.82 TSHR (0.42) KDM4ETSHRGAAMEN1KMT2A
SCHEMBL8786560 0.81 KDM4E (0.49) KDM4ETSHRGAAHTTPDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240027903-A1 Resist Material And Patterning Process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-01-25 US disclosed
US-20050227978-A1 Fibrosis inhibitor SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2005-10-13 US disclosed
EP-1479384-A1 FIBROSIS INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-11-24 EP disclosed
US-20040209939-A1 Pyrrole derivatives SUMITOMO PHARMACEUTICALS CO., LTD. 2004-10-21 US disclosed
US-6759429-B2 HAVING TRANSFORMING GROWTH FACTOR- BETA INHIBITORY ACTIVITY AND BEING USEFUL AS FIBROSIS INHIBITORS FOR ORGANS OR TISSUES SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2004-07-06 US disclosed
US-20030181496-A1 Pyrrole derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2003-09-25 US disclosed
EP-1310485-A1 PYRROLE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227978-A1 Fibrosis inhibitor SMAD3, MMP1, SMAD2 KDM4E 2031/4885TSHR 2553/4885GAA 4229/4885
US-20030181496-A1 Pyrrole derivatives NCOA1, PKD1, NR3C2 KDM4E 430/4885TSHR 2806/4885GAA 4826/4885
US-20240027903-A1 Resist Material And Patterning Process LBR, HNRNPU, EWSR1 KDM4E 778/4885TSHR 2364/4885GAA 3050/4885
US-20040209939-A1 Pyrrole derivatives NCOA1, PKD1, NCOR1 KDM4E 477/4885TSHR 2862/4885GAA 4826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.